AbbVie Reports long-term follow-up Data for Inclisiran in Follicular lymphoma

AbbVie today announced long-term follow-up results for inclisiran in patients with follicular lymphoma. The study demonstrated that inclisiran improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of follicular lymphoma and support the continued development of inclisiran in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.